| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Parminder Singh, Anil Gautam, Marissa Trujillo, James Galligan, Lisa Hensley, Pankaj Kapahi, Andrzej Bartk. Growth Hormone Excess Drives Liver Aging via increased Glycation stress. bioRxiv : the preprint server for biology. 2025-01-20. PMID:39829894. |
pathological conditions such as acromegaly or pituitary tumors result in elevated circulating gh levels, which have been implicated in a spectrum of metabolic disorders, potentially by regulating liver metabolism. |
2025-01-20 |
2025-01-23 |
mouse |
| David S McLaren, Nikolaos Kyriakakis, Khyatisha Seejore, Julie Lynch, Robert D Murra. Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality? Clinical endocrinology. 2024-12-31. PMID:39737607. |
with the current therapeutic modalities available to endocrinologists, control of gh and igf-i is now possible in almost all patients with acromegaly with multi-modality therapy. |
2024-12-31 |
2025-01-02 |
Not clear |
| David S McLaren, Nikolaos Kyriakakis, Khyatisha Seejore, Julie Lynch, Robert D Murra. Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality? Clinical endocrinology. 2024-12-31. PMID:39737607. |
despite biochemical control of gh and igf-i, patients with acromegaly continue to experience impaired quality of life. |
2024-12-31 |
2025-01-02 |
Not clear |
| Betina Biagetti, Marta Araujo-Castro, Mónica Marazuela, Manel Puig-Doming. Treatment of acromegaly-induced diabetes: an updated proposal. Pituitary. vol 28. issue 1. 2024-12-31. PMID:39738706. |
increased cardiovascular risk is much higher when acromegaly is complicated with diabetes, thus requiring a holistic management that addresses also these specific characteristics which differ from those of classical type 2 diabetes.the optimal management of diabetes in acromegaly requires not only an effective control of carbohydrate disturbances per se, but also the concurrent control of gh hypersecretion as it will directly impact on glucose control. |
2024-12-31 |
2025-01-03 |
Not clear |
| Betina Biagetti, Marta Araujo-Castro, Mónica Marazuela, Manel Puig-Doming. Treatment of acromegaly-induced diabetes: an updated proposal. Pituitary. vol 28. issue 1. 2024-12-31. PMID:39738706. |
if surgical treatment is not effective to normalize gh and igf-1 levels, pharmacologic therapy for acromegaly must consider the metabolic effects that the different drugs may induce, as some of them may worsen carbohydrate metabolism. |
2024-12-31 |
2025-01-03 |
Not clear |
| Yasuyuki Kinoshita, Akira Taguchi, Fumiyuki Yamasaki, Shumpei Onishi, Atsushi Tominaga, Nobutaka Hori. Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests. Pituitary. vol 28. issue 1. 2024-12-26. PMID:39724486. |
management policy for postoperative acromegaly patients with normal igf-1 and high gh levels on oral glucose tests. |
2024-12-26 |
2024-12-29 |
Not clear |
| Yasuyuki Kinoshita, Akira Taguchi, Fumiyuki Yamasaki, Shumpei Onishi, Atsushi Tominaga, Nobutaka Hori. Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests. Pituitary. vol 28. issue 1. 2024-12-26. PMID:39724486. |
acromegaly patients occasionally achieve either of the remission criterion of igf-1 or gh level postoperatively; however, treatment for patients with discordant igf-1 and gh levels remains unclear. |
2024-12-26 |
2024-12-29 |
Not clear |
| Haixiang Li, Ziqi Li, Tianshun Feng, Yuyang Chen, Jiansheng Zhong, Liangfeng Wei, Shousen Wan. Predictors of growth hormone level on postoperative day one in patients with acromegaly. Endocrine. 2024-12-20. PMID:39707075. |
the growth hormone (gh) level on postoperative day one (pod1), i.e., pod1gh, holds significant value in assessing surgical efficacy and predicting long-term remission in patients with acromegaly. |
2024-12-20 |
2024-12-24 |
Not clear |
| Haixiang Li, Ziqi Li, Tianshun Feng, Yuyang Chen, Jiansheng Zhong, Liangfeng Wei, Shousen Wan. Predictors of growth hormone level on postoperative day one in patients with acromegaly. Endocrine. 2024-12-20. PMID:39707075. |
this study aims to explore the factors that influence the gh level of pod1 after microscopic transsphenoidal surgery (mtss) in patients with acromegaly, providing insights for preoperative clinical decisions. |
2024-12-20 |
2024-12-24 |
Not clear |
| Kevin C J Yuen, Rikke Hjortebjerg, Ashok Ainkaran Ganeshalingam, David R Clemmons, Jan Frysty. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin. Frontiers in endocrinology. vol 15. 2024-12-12. PMID:39665021. |
disease states of gh excess (e.g., acromegaly) and gh deficiency (e.g., congenital isolated gh deficiency) are characterized by increased and decreased gh, igf-i and insulin levels, respectively, where the gh/igf-i relationship is reflected by a "primary association". |
2024-12-12 |
2024-12-14 |
Not clear |
| Reetobrata Basu, Cesar L Boguszewski, John J Kopchic. Growth Hormone Action as a Target in Cancer: Significance, Mechanisms and Possible Therapies. Endocrine reviews. 2024-12-10. PMID:39657053. |
hypo or hypersecretion of endocrine gh results in two pathologic conditions, namely gh deficiency (ghd) and acromegaly. |
2024-12-10 |
2024-12-21 |
Not clear |
| Reetobrata Basu, Cesar L Boguszewski, John J Kopchic. Growth Hormone Action as a Target in Cancer: Significance, Mechanisms and Possible Therapies. Endocrine reviews. 2024-12-10. PMID:39657053. |
this pleiotropy of gh's effects is puzzling, but the association with cancer-risk automatically raises a concern for patients with acromegaly and for individuals treated with gh. |
2024-12-10 |
2024-12-21 |
Not clear |
| Pietro Maffei, Francesca Dassi. Medical Treatment of Acromegaly: What's New? Frontiers of hormone research. vol 55. 2024-11-25. PMID:39586262. |
acromegaly is a chronic and progressive disorder caused by growth hormone (gh) and insulin-like growth factor 1 (igf-1) excess, responsible for the onset of multiple systemic complications. |
2024-11-25 |
2024-11-28 |
Not clear |
| Federica Guaraldi, Luisa Di Sciascio, Tarik Ziyad Tarik Shwaish, Matteo Zoli, Diego Mazzatenta, Sofia Asiol. GH-Secreting Adenoma or Tumor? Issues in Pituitary Neoplasms Nomenclature, Classification, and Characterization. Frontiers of hormone research. vol 55. 2024-11-25. PMID:39586264. |
acromegaly is a rare disorder characterized by chronic hypersecretion of growth hormone (gh) and, consequently, of its mediator, insulin-like growth factor 1 (igf-1), due in >95% of the cases to a gh-secreting pituitary adenoma (pa)/pituitary neuroendocrine tumor (pitnet). |
2024-11-25 |
2024-11-28 |
Not clear |
| Agnieszka Włochacz, Paweł Krzesiński, Beata Uziębło-Życzkowska, Przemysław Witek, Grzegorz Zieliński, Grzegorz Gielera. Echocardiographic and Impedance Cardiography Analysis of Left Ventricular Diastolic Function in Acromegaly Patients. Medical science monitor : international medical journal of experimental and clinical research. vol 30. 2024-11-22. PMID:39573826. |
background due to the chronic effects of excess growth hormone (gh) and insulin-like growth factor-1 (igf-1), patients with acromegaly (ac) may develop acromegalic cardiomyopathy with biventricular hypertrophy, systolic and diastolic dysfunction, resulting in congestive heart failure. |
2024-11-22 |
2024-11-24 |
Not clear |
| Stefano Frara, Matteo Acanfora, Vincenzo Franzese, Maria Luisa Brandi, Marco Losa, Andrea Giustin. Novel approach to bone comorbidity in resistant acromegaly. Pituitary. 2024-11-21. PMID:39570564. |
among them, acromegaly osteopathy and fragility (vertebral and hip) fractures have emerged as frequent and precocious events in the natural history of the disease, being correlated with longer disease duration and higher growth hormone (gh) levels, accounting for patients' reported poor quality of life, physical performance and other life-impacting complications. |
2024-11-21 |
2024-11-23 |
Not clear |
| Marta Araujo-Castro, Betina Biagetti, Edelmiro Menéndez Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich, Rogelio García Centeno, Laura González, María Dolores Ollero García, Ana Irigaray Echarri, María Dolores Moure Rodríguez, Cristina Novo-Rodríguez, María Calatayud, Rocío Villar, Ignacio Bernabéu, Cristina Alvarez-Escola, Pamela Benítez Valderrama, Carmen Tenorio-Jimenéz, Pablo Abellán Galiana, Eva Venegas Moreno, Inmaculada González Molero, Pedro Iglesias, Concepción Blanco, Fernando Vidal-Ostos De Lara, Paz de Miguel, Elena López Mezquita, Felicia Hanzu, Iban Aldecoa, Cristina Lamas, Silvia Aznar, Anna Aulinas, Anna Calabrese, Paola Gracia, José María Recio-Córdova, Mariola Aviles, Diego Asensio-Wandosel, Miguel Sampedro, Ignacio Ruz-Caracuel, Rosa Camara, Miguel Paja, Carmen Fajardo-Montañana, Mónica Marazuela, Manel Puig-Doming. Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases. The Journal of clinical endocrinology and metabolism. vol 109. issue 12. 2024-11-17. PMID:38436926. |
few data exist about the clinical course of acromegaly, surgical and medical outcomes in patients with gh- and prolactin cosecreting pituitary adenomas (gh&prl-pas). |
2024-11-17 |
2024-11-22 |
Not clear |
| Ana Irigaray Echarri, M Dolores Ollero García-Agulló, José Jorge Ortez Toro, Idoya Zazpe Ceno. Endothelial dysfunction and vascular abnormalities in acromegaly. A case report. Neurocirugia (English Edition). 2024-10-30. PMID:39477091. |
in patients with acromegaly, the pleiotropic effects of gh and igf-1 have been associated with the development of endothelial dysfunction and vascular abnormalities. |
2024-10-30 |
2024-11-02 |
Not clear |
| Kento Takahara, Ryota Tamura, Erika Isomura, Yohei Kitamura, Ryo Ueda, Masahiro Tod. Variable anatomical features of acromegaly in the nasal cavity and paranasal sinuses: implications for endoscopic endonasal transsphenoidal surgery. Acta neurochirurgica. vol 166. issue 1. 2024-10-15. PMID:39404864. |
growth hormone (gh)-secreting pituitary neuroendocrine tumors (pitnets) are the most common cause of acromegaly. |
2024-10-15 |
2024-10-17 |
Not clear |
| Diego Ferone, Pamela Freda, Laurence Katznelson, Federico Gatto, Pinar Kadioğlu, Pietro Maffei, Jochen Seufert, Julie M Silverstein, Joanna L Spencer-Segal, Elena Isaeva, Alexander Dreval, Maria Harrie, Agneta Svedberg, Fredrik Tiber. Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. The Journal of clinical endocrinology and metabolism. 2024-10-08. PMID:39378125. |
acromegaly, characterized by excessive growth hormone (gh) and insulin-like growth factor-1 (igf-1), impacts quality of life (qol) and mortality. |
2024-10-08 |
2024-10-11 |
Not clear |